Lyfebulb and Novo Nordisk A/S announce the ten patient entrepreneur finalists for the Lyfebulb-Novo Nordisk Innovation Award

The Award Recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for Management of Diabetes Using Consumer Products, Medical Devices, or Healthcare Information Technologies

Print
| Source: Lyfebulb

NEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- The top 10 finalists for the Lyfebulb-Novo Nordisk Innovation Award have been announced today.

The Award spotlights outstanding patient entrepreneurs’ innovative efforts and ideas to better manage diabetes via consumer products, medical devices, or healthcare information technology.

The ten finalists are:

Shilo Ben-Zeev, Smartzyme, Israel;
Jeff Dachis, OneDrop, USA;
Shantanu Gaur, MD, Allurion, USA;
Matt Loper, Wellth, USA;
Charles O’Connell, FitScript, USA;
Scott Smith, Socrates, USA;
Anna Sjoberg, Anna PS, Sweden;
John Sjolund, Patients Pending Ltd, UK;
David Weingard, Fit4D, USA;
Brianna Wolin, FindYourDitto, USA.

The 10 finalists have been narrowed down from more than 50 applications from 15 countries around the world, by the Lyfebulb founders and senior device researchers from Novo Nordisk A/S.

The finalists will all attend the Innovation Summit December 6-7, 2016 hosted by Novo Nordisk in Copenhagen, Denmark. The Summit provides an opportunity for visibility and recognition in this highly competitive arena as well as professional discussion and inspiration for developing ideas further. The winner will be announced on December 7, 2016.

“All applications were of tremendous quality and we were thrilled to have such a large number of people applying for this Award during its first year. We are certain the Summit will be a great opportunity for both the entrepreneurs and for Novo Nordisk researchers to further their respective business goals and missions,” says Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “We believe that patient entrepreneurs are an important part of the future for people living with chronic disease, and the companies that are bringing innovative products to market for this group of people.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds: “Patient entrepreneurs are making a real difference to advance the management and care of diabetes. I am looking forward to meeting the ten finalists and share perspective on what rally all of us around a common goal: changing life with diabetes.”

More information on the selection process, the Summit and the 10 finalists can be found on the Lyfebulb Website.

About Lyfebulb
Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW.
See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD
CEO Lyfebulb
Phone: 917-575-0210
Email: karin@lyfebulb.com

Consumer Press Contact for Lyfebulb:
People’s Revolution - Kelly Cutrone & Simone Francese
62 Grand Street, 3rd Floor New York, New York 10013
Phone: 212-274-0400
Email: simone.francese@peoplesrevolution.com